Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
62
resultados
Última actualización
17/09/2025 [07:40:00]
Resultados 50 a 62 de 62
Resumen de: MX2025003197A
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: TW202502373A
The invention provides application of IL-27 protein in preparation of a product for treating Alzheimer's disease, and belongs to the technical field of biological medicine. The IL-27 protein is a recombinant IL-27 protein, and aims at a treatment target IL-27, and comprises a mouse source IL-27, a human source IL-27, and a mammal IL-27 except the mouse source IL-27 and the human source IL-27. The recombinant IL-27 protein provided by the invention can effectively relieve Alzheimer's disease caused by A beta deposition, and can be selectively and specifically combined with a receptor of the recombinant IL-27 protein, so that the accuracy of a detection result is ensured; the specificity of the protein receptor is highly expressed in the dentate gyrus region of the sea horse, so that the drug targeting is ensured to the greatest extent; the recombinant IL-27 protein has a good application prospect, can quickly and effectively improve and relieve memory impairment and other behaviors of mice with Alzheimer's disease, and has a clinical transformation value.
Resumen de: KR20250113108A
본 발명은아밀로이드베타 검출을 위한 탄소나노셀룰로오스-팔라듐 나노복합체 제조방법 및 이의 용도에 관한 것으로, 본 발명의 제조방법에 따른 탄소나노셀룰로오스-팔라듐 나노복합체(Pd-CNC)는 아밀로이드베타(Amyloid-β)에 대하여 높은 친화도를 가져 이를 바이오센서로 사용하는 경우 종래의 비색 센서에 비해 적은 시료량을 요구하며, 검출 민감도가 현저히 우수한 효과가 있다. 또한, 종래의 비색 센서와 달리 값비싼 항체를 요구하지 않으며 간단한 장비로 아밀로이드베타를 검출할 수 있어 검출 비용이 저렴하다는 장점이 있다.
Resumen de: CN120369958A
The invention belongs to the field of disease detection, and particularly relates to a double-antibody sandwich kit for detecting beta-amyloid protein and application of the double-antibody sandwich kit. A capture antibody used by the kit is 5D8, a heavy chain variable region of the capture antibody comprises HCDR1-3 as shown in SEQ ID NO: 3-5, and a light chain variable region of the capture antibody comprises LCDR1-3 as shown in SEQ ID NO: 6-8; a detection antibody used by the kit is 7H11, a heavy chain variable region of the detection antibody comprises HCDR1-3 as shown in SEQ ID NO: 11-13, and a light chain variable region of the detection antibody comprises LCDR1-3 as shown in SEQ ID NO: 14-16. The detection kit is high in beta-amyloid protein detection sensitivity and high in specificity, and has important significance in diagnosis, prevention and treatment of Alzheimer's disease.
Resumen de: US2025238922A1
Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.
Resumen de: US2025237652A1
Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
Resumen de: US2025235464A1
Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.
Resumen de: WO2025155794A1
The present inventive concept provides a subject's fecal protein bioprofile and methods for establishing the same. Also provided are methods of determining a subject's risk for developing an inflammatory disorder, a neurological disorder, a neurodegenerative disorder, or a disorder associated with aging or monitoring the same. The inventive concept further provides kits for use in the methods described herein.
Resumen de: EP4589015A2
In vitro method for the diagnosis of synucleinopathies. The present invention is directed to an in vitro method for the specific diagnosis of a synucleinopathy and/or for the differential diagnosis of a synucleinopathy from Alzheimer disease (AD). In a preferred embodiment, the synucleinopathy is Dementia with Lewy bodies (DLB) or Parkinson's disease (PD).
Resumen de: CN120352634A
The invention provides a kit for detecting Alzheimer's disease related protein and application thereof, the kit is characterized in that sucrose is added into a fluorescent reagent diluent to improve the stability of Alzheimer's disease related protein in a detection sample, and HEPES is added into the sample diluent to improve the stability of the Alzheimer's disease related protein in the detection sample. Blocking agents HBR6 and HBR11 are added into a reaction buffer solution to improve the specific binding capacity of the related protein, so that the content of the Alzheimer disease related protein in a sample is accurately detected through 2.5-step room-temperature oscillation incubation, and the detection time is greatly shortened; the invention also optimizes the working concentration of SA-PE, the mixed molar ratio of antibody to biotin and incubation conditions. The kit provided by the invention is simple to operate, not only improves the detection efficiency, the detection accuracy, the specificity and the sensitivity, but also facilitates clinical detection application, can reduce the reagent and labor cost, is good in repeatability, and has a relatively good application prospect.
Nº publicación: CN120349377A 22/07/2025
Solicitante:
SANYA RESEARCH INSTITUTE OF HENAN UNIV
HENAN UNIV
\u6CB3\u5357\u5927\u5B66\u4E09\u4E9A\u7814\u7A76\u9662
Resumen de: CN120349377A
The invention belongs to the technical field of biological medicines, and particularly relates to a wheat peptide with antioxidant stress activity and a preparation method and application thereof. The invention provides a wheat peptide with antioxidant stress activity. The amino acid sequence of the wheat peptide is as shown in SEQ ID NO: 1. The invention discloses a wheat peptide FGWPGPK for protecting oxidative stress nerve cells as well as a screening method and application of the wheat peptide FGWPGPK. A target peptide fragment is identified from wheat germs through enzymolysis and multi-dimensional screening strategies, and it is proved that the target peptide fragment can significantly improve the survival rate of PC-12 cells damaged by H2O2 (72.88%) and reduce the ROS level (125.54%). The peptide fragment has strong antioxidant activity and nerve targeting property, and is suitable for preventing and treating neurodegenerative diseases such as Alzheimer's disease.
BOPI
Sede Electrónica
